Document is current

Article History

Received: 31 May 2024

Accepted: 2 September 2024

First Online: 27 September 2024

Declarations

:

: Written informed consent was obtained from each participant before enrolment taking into account the GDPR (European Union General Data Protection Regulation) requirements. The protocol (N° EudraCT / ID-RCB: 2021-A00348-33) was conducted in accordance with the Declaration of Helsinki and French law for research involving human subjects (known as Loi Jardé). The protocol was approved by Ethics Committees: the committee for protection of participants engaged in research “CPP Nord-Ouest IV” (file number: 21.02.12.47147) and the French national data protection authority “CNIL” (Commission Nationale Informatique et Liberté, authorization number 921111v1).

: Not applicable.

: PL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astrazeneca, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur and Support for attending meetings and/or travel from Pfizer, Sanofi Pasteur. JM has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Biogen, BMS, Boerhinger Ingelheim, Galapagos, GSK, Fresenius Kabi, Lilly, Mylan, Novartis, Pfizer, Sanofi and grants outside the submitted work from Lilly, Novartis. JPS has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer and Astrazeneca. OL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi Pasteur; Pfizer, Janssen and, non-financial support from Sanofi Pasteur; Pfizer, Janssen, GlaxoSmithKline and grant from GlaxoSmithKline. The other authors declare having no conflict of interest.